Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results

IJID Regions(2023)10.1016/j.ijregi.2023.11.002Source: DataRank Database

Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study – final study results is a research paper published in IJID Regions (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.33)OA: goldTopics (28)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Emily Shava ORCID,Alane Izu ORCID,Tendani Gaolathe,Lesego Kuate,Adam K. Walker ORCID

Live enrichment

PubMed:38090729 PMC:PMC10714336 OpenAlex:https://openalex.org/W4388562895

Fogarty International Center

Grant: K43 TW012350

Fogarty International Center

Grant: D8111C00013 / ESR-21-21311

Bill and Melinda Gates Foundation

Grant: INV-033558

National Institutes of Health

Grant: 1K43TW012350-01

Viral Diversity an Innovative Biomarker for Refining Estimates of HIV Incidence

Tindall Foundation

AstraZeneca

AstraZeneca UK Limited

FWCI

0.33

Citation Percentile

0.6%

Citation Trend

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ijregi.2023.11.002

publisherhttps://doi.org/10.1016/j.ijregi.2023.11.002

publisherhttps://api.elsevier.com/content/article/PII:S2772707623001091?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2772707623001091?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38090729

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations0303 health sciences03 medical and health sciences

Keywords

Coronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationIncidence (geometry)2019-20 coronavirus outbreakVirologyOpen labelImmunologyInternal medicineClinical trialDiseaseInfectious disease (medical specialty)Outbreakantibody responsesBotswanaAstrazenecaCovid-19 VaccinationAzd 1222SDG-03: Good health and well-beingCOVID-19 pandemicOriginal Report333

Sustainable Development Goals

SDG 0: Good health and well-being